(Q50682780)

17 March 2018

title

Economic decision analysis model of screening for lung cancer. (English)

1 reference

17 March 2018

1 reference

1

1 reference

17 March 2018

author name string

Simpson KN

series ordinal

2

1 reference

17 March 2018

Earle CC

series ordinal

3

1 reference

17 March 2018

Chu CW

series ordinal

4

1 reference

17 March 2018

publication date

1 September 2001

1 reference

17 March 2018

European Journal of Cancer

published in

1 reference

17 March 2018

volume

37

1 reference

17 March 2018

page(s)

1759-1767

1 reference

17 March 2018

issue

14

1 reference

17 March 2018

Are increasing 5-year survival rates evidence of success against cancer?

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2801%2900205-2

7 January 2021

Revisions in the International System for Staging Lung Cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2801%2900205-2

7 January 2021

Peripheral lung cancer: screening and detection with low-dose spiral CT versus radiography

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2801%2900205-2

7 January 2021

Early Lung Cancer Action Project: overall design and findings from baseline screening.

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2801%2900205-2

7 January 2021

Screening for lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2801%2900205-2

7 January 2021

Potential cost-effectiveness of one-time screening for lung cancer (LC) in a high risk cohort.

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2801%2900205-2

7 January 2021

Systematic overview of cost-utility assessments in oncology

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2801%2900205-2

7 January 2021

Medicare payments from diagnosis to death for elderly cancer patients by stage at diagnosis.

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2801%2900205-2

7 January 2021

Stage, age, comorbidity, and direct costs of colon, prostate, and breast cancer care

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2801%2900205-2

7 January 2021

Lung cancer mortality in the Mayo Lung Project: impact of extended follow-up.

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2801%2900205-2

7 January 2021

Length and lead time biases in radiologic screening for lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2801%2900205-2

7 January 2021

Screening for lung cancer. Another look; a different view

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2801%2900205-2

7 January 2021

Overdiagnosis: An underrecognized cause of confusion and harm in cancer screening.

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2801%2900205-2

7 January 2021

Screening for lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2801%2900205-2

7 January 2021

Surgical therapy of early non-small cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2801%2900205-2

7 January 2021

The effect of surgical treatment on survival from early lung cancer. Implications for screening

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2801%2900205-2

7 January 2021

Prognostic assessment of 1310 patients with non-small-cell lung cancer who underwent complete resection from 1980 to 1993

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2801%2900205-2

7 January 2021

Results of surgery for primary lung cancer based on the new international staging system.

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2801%2900205-2

7 January 2021

A cost utility analysis of mammography screening in Australia.

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2801%2900205-2

7 January 2021

Screening for prostate cancer. A decision analytic view

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2801%2900205-2

7 January 2021

Five-hundred life-saving interventions and their cost-effectiveness

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2801%2900205-2

7 January 2021

The value of mammography screening in women under age 50 years

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2801%2900205-2

7 January 2021

Screening for mild hypertension: costs and benefits

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2801%2900205-2

7 January 2021

Cost-effectiveness of screening for colorectal cancer in the general population.

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2801%2900205-2

7 January 2021

10.1016/S0959-8049(01)00205-2

Identifiers

DOI

1 reference

17 March 2018

PubMed ID

11549429

1 reference

17 March 2018